Abstract
Non-opioid analgesics including both selective and non-selective cyclooxygenase (COX) inhibitors and acetaminophen are the most widely used treatments for pain. Inhibition of COX is thought to be largely responsible for both the therapeutic and adverse effects of this class of drugs. Accumulating evidence over the past two decades has demonstrated effects of non-opioids beyond the inhibition of COX and prostaglandin synthesis that might also explain their therapeutic and adverse effects. These include their interaction with endocannabinoids, nitric oxide, monoaminergic, and cholinergic systems. Moreover, the recent development of microarray technology that allows the study of human gene expression suggests multiple pathways that may be related to the analgesic and anti-inflammatory effects of non-opioids. The present review will discuss the multiple actions of non-opioids and their interactions with these systems during inflammation and pain, suggesting that COX inhibition is an incomplete explanation for the actions of non-opioids and proposes the involvement of multiple selective targets for their analgesic, as well as, their adverse effects.
Keywords: NSAIDs, endocannabinoids, monoaminergic systems, cholinergic system, nitric oxide, interleukin-6, matrix metalloproteinases, inflammatory pain
Current Molecular Pharmacology
Title: Mechanisms of Non-Opioid Analgesics Beyond Cyclooxygenase Enzyme Inhibition
Volume: 2
Author(s): May Hamza and Raymond A. Dionne
Affiliation:
Keywords: NSAIDs, endocannabinoids, monoaminergic systems, cholinergic system, nitric oxide, interleukin-6, matrix metalloproteinases, inflammatory pain
Abstract: Non-opioid analgesics including both selective and non-selective cyclooxygenase (COX) inhibitors and acetaminophen are the most widely used treatments for pain. Inhibition of COX is thought to be largely responsible for both the therapeutic and adverse effects of this class of drugs. Accumulating evidence over the past two decades has demonstrated effects of non-opioids beyond the inhibition of COX and prostaglandin synthesis that might also explain their therapeutic and adverse effects. These include their interaction with endocannabinoids, nitric oxide, monoaminergic, and cholinergic systems. Moreover, the recent development of microarray technology that allows the study of human gene expression suggests multiple pathways that may be related to the analgesic and anti-inflammatory effects of non-opioids. The present review will discuss the multiple actions of non-opioids and their interactions with these systems during inflammation and pain, suggesting that COX inhibition is an incomplete explanation for the actions of non-opioids and proposes the involvement of multiple selective targets for their analgesic, as well as, their adverse effects.
Export Options
About this article
Cite this article as:
Hamza May and Dionne A. Raymond, Mechanisms of Non-Opioid Analgesics Beyond Cyclooxygenase Enzyme Inhibition, Current Molecular Pharmacology 2009; 2 (1) . https://dx.doi.org/10.2174/1874467210902010001
DOI https://dx.doi.org/10.2174/1874467210902010001 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application
Current Gene Therapy Nutritional Overview on the Management of Type 2 Diabetes and the Prevention of its Complications
Current Diabetes Reviews Effect of Sodium Taurocholate on Omeprazole Buccal Adhesive Tablet: Physicochemical Characterization and Pharmacokinetics in Hamster
Current Pharmaceutical Analysis Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Profiling of Enzymatic Activities Using Peptide Arrays
Mini-Reviews in Organic Chemistry The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits
CNS & Neurological Disorders - Drug Targets Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Engineering of Nanoemulsions for Drug Delivery
Current Drug Delivery Editorial (Thematic Issue: Immunotherapy in Central Nervous System)
Current Pharmaceutical Biotechnology Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Subject Index to Volume 3
Mini-Reviews in Medicinal Chemistry Effects of Eleutherococcus senticosus Cortex on Recovery from the Forced Swimming Test and Fatty Acid β-Oxidation in the Liver and Skeletal Muscle of mice
The Natural Products Journal Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Chemical Crosslinking: Role in Protein and Peptide Science
Current Protein & Peptide Science Modulation of the Endocannabinoid System by Lipid Rafts
Current Medicinal Chemistry TLR2 and TLR4 Expression During Bacterial Infections
Current Pharmaceutical Design Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Editorial
Inflammation & Allergy - Drug Targets (Discontinued) Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets